Bleeding Disorders Canada, formerly the Canadian Hemophilia Society (CHS), is proud to announce its call for applications for its research programs for the 2026–2027 grant period.

The Canadian Hemophilia Society became Bleeding Disorders Canada in July 2026. During this transition period, research grant documents may include references to both Bleeding Disorders Canada and the Canadian Hemophilia Society (CHS) as we update our materials to reflect our new name.

The deadline to submit applications for all the programs is NOVEMBER 27, 2026. Please see below details of each research grant and links to apply. Feel free to reach out to Natalie Philbert, National Programs Director, if you have any questions or require assistance at nphilbert@hemophilia.ca.

DREAM OF A CURE

The CHS provides scientific research grants and studentships aimed at developing treatments for hemophilia A and B, von Willebrand disease, rare factor deficiencies, and platelet function disorders.

Individual grants valued at $75,000 per year and per project will be awarded to researchers for a maximum of $150,000 which can be expended over 2 or 3 years.

Grants will also be available for Canadian medical or science students for up to 4 months, for a maximum stipend of $6,000 each.

Examples of previous research awarded include: Human Endometrial Endothelial Cells (HEECs): A novel cellular method for understanding the pathophysiology of heavy menstrual bleeding in von Willebrand Disease by Dr. Mackenzie Bowman & Dr. Paula James

Online applications for the 2026-27 granting period, previous and current research, as well as the general criteria and conditions can be accessed at: www.hemophilia.ca/chs-dream-of-a-cure-research-program.

______________________________

PFIZER CARE UNTIL CURE RESEARCH PROGRAM

In partnership with Pfizer, the CHS provides research grants to Canadian investigators to conduct research on medical and psychosocial aspects of bleeding disorders, including hemophilia, people with von Willebrand disease or other inherited bleeding disorders, people with related conditions such as HIV or hepatitis C infection, and carriers of an inherited bleeding disorder.

Individual grants valued at $75,000 per year and per project will be awarded to researchers for a maximum of $150,000 which can be expended over 2 or 3 years.

Examples of previous research awarded include: A Canadian Roadmap and Action Plan for Hemophilia Gene Therapies: A Mixed-Method Study by Dr. Roy Khalifé

Online application forms for the 2026-27 granting period, previous and current research, general criteria and specific areas of interest can be accessed at: www.hemophilia.ca/the-chspfizer-care-until-cure-research-program

Please feel free to distribute this information to others who may be interested in applying. The research must be conducted in Canada by researchers affiliated with Canadian universities and not-for-profit-related organizations.

The Project Grant program is expected to:

• Support a diverse portfolio of health-related research and knowledge translation proposals at any stage, from discovery to application, including commercialization;
• Promote relevant collaborations across disciplines, professions, and sectors; and
• Contribute to the creation and use of health-related knowledge.

The PCC Fellowship Program supports qualified scientists interested in the field of anti-doping, committed to meaningful research, and demonstrating potential for long-term contribution to the field of anti-doping scien​ce. Fellows selected by the PCC participate in a two-year program. Fellows gain practical knowledge from a U.S.-based, WADA-accredited laboratory and conduct research supporting the anti-doping field.

PCC Research Grants support projects advancing knowledge in the anti-doping sphere. Pre-Applications are reviewed two times per year: February 1st and August 1st. Applicants are encouraged to review the research priorities of the PCC before applying. Applicants that are invited to complete a full application, are encouraged to review the instructions below. Full Applications are due on March 1st and September 1st.

Applications for the 2027 Pierre Elliott Trudeau Foundation Scholarship are open to doctoral students who are in the first or second year of their PhD program at the time of application.

Your field of study must be broadly related to the humanities or social sciences and address issues that are relevant to Canada’s future. Your PhD research must align with at least one of the Foundation’s four themes:

• Human Rights and Dignity
• Responsible Citizenship
• Canada and the World
• People and their Natural Environment

The Canadian Cancer Society Awards for Excellence in cancer research recognize individuals who have made, and are making, valuable contributions to the cancer research ecosystem in Canada. Recipients are leaders in their fields who exemplify excellence in science and outstanding service to the scientific community. Posthumous nominations are not eligible.  Recipients will be recognized and will receive a personalized glass plaque commemorating their award. Each award also comes with a $20,000 contribution to the recipient’s research program.  

Canadian Cancer Society Lifetime Contribution Prize

The Lifetime Contribution Prize will be given to an esteemed investigator whose contributions to cancer research in Canada extend beyond traditional research accomplishments and outputs.  

Canadian Cancer Society Inclusive Excellence Prize

The Inclusive Excellence Prize will be given to an individual who has demonstrated commitment, leadership and (potential for) impact in the advancement of Canada’s cancer research ecosystem from an equity, diversity, inclusion and accessibility lens, both among those conducting the research and those benefiting from its outcomes. 

Canadian Cancer Society Robert L. Noble Prize

The Robert L. Noble Prize is given for outstanding achievements in basic biomedical cancer research. It is named in honour of Dr Noble, an esteemed Canadian investigator whose research in the 1950s led to the discovery of vinblastine, a widely used anticancer drug. At the time, vinblastine was one of the most effective treatments available for Hodgkin lymphoma.

Canadian Cancer Society O. Harold Warwick Prize

The O. Harold Warwick Prize is given for outstanding achievements in cancer control research. It is named in honour of Dr Warwick, a pioneering researcher in cancer control and treatment, and the first executive director of the former National Cancer Institute of Canada and the Canadian Cancer Society.  

Canadian Cancer Society Bernard and Francine Dorval Prize

The Bernard and Francine Dorval Prize is given to an early career investigator whose outstanding contributions to basic biomedical research have the potential to lead or have already led to improved understanding of cancer treatments and/or cures. It is named in honour of Bernard and Francine Dorval, whose longstanding support of CCS has helped to raise more than two million dollars in support of CCS-funded research, policy work, and programs. 

Canadian Cancer Society William E. Rawls Prize

The William E. Rawls Prize is given to an early career investigator whose outstanding contributions have the potential to lead to or have already led to important advances in cancer control. It is named in honour of Dr Rawls, past president of the former National Cancer Institute of Canada. His research focused on viruses, particularly those involved in chronic diseases and cervical cancer. 

If you are interested in being nominated for one of the above awards, please contact Anne Klymenko, Director, Office of Research Services at aklymenk@lakeheadu.ca.